Early access to gold-based treatment for ALS
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial provides access to an experimental medicine called CNM-Au8 (a gold-based suspension) for people with ALS. The goal is to see if it can slow disease progression. It is an 'expanded access' program, which means it is for people who are not eligible for other clinical trials.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed ALS diagnosis by a specialist (either definite, probable, or possible ALS).
- You must be at least 18 years old.
- You must be able to swallow the liquid medicine, or take it through a feeding tube.
- Your doctor must expect you to live for more than 6 months.
- You must not be allergic to gold.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding two supplements (EH-301 and N-acetylcysteine) to the standard ALS medicine Riluzole can help slow the disease. It is for people diagnosed with ALS within the last 18 months who still have good breathing and daily function.
This trial studies an experimental drug called LTX-002 for people with ALS. It aims to see if the drug is safe and can slow down the disease.
This study tests a supplement called acetyl-L-carnitine (ALCAR) to see if it can slow the progression of ALS. It is for people in the early stages of the disease who are already taking riluzole and have good lung and muscle function.
This trial tests whether a new medicine, made of tiny capsules containing a protein called nerve growth factor, can help people with ALS. It aims to see if the treatment can slow the disease and improve symptoms.
This trial tests a medication called acamprosate to see if it can slow down ALS in people who have a specific genetic change (C9orf72). If you have this gene change and ALS, this study might offer a new treatment option.
This trial tests a new treatment aimed at restoring the function of a gene called UNC13A in people with ALS. It involves multiple clinic visits, MRI scans, and spinal taps to see if the treatment is safe and may slow the disease.
Hear when a new Amyotrophic Lateral Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.